Sign in or create an account to add this stock to your watchlist.
About BioLineRx (NASDAQ:BLRX)
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company's other therapeutic candidates comprise BL-1040, a resorbable polymer solution for use in the prevention of ventricular remodeling; BL-9020, which is a monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; and BL-1230, a cannabinoid receptor type 2 intended as an anti-inflammatory treatment for dry eye syndrome. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLRX
CUSIPN/A
Phone972-2548-9100
Debt
Debt-to-Equity RatioN/A
Current Ratio7.37
Quick Ratio7.50
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.46 per share
Price / Book1.98
Profitability
EPS (Most Recent Fiscal Year)($0.27)
Net Income$-24,350,000.00
Net MarginsN/A
Return on Equity-47.07%
Return on Assets-41.75%
Miscellaneous
Employees43
Outstanding Shares106,490,000
BioLineRx (NASDAQ:BLRX) Frequently Asked Questions
What is BioLineRx's stock symbol?
BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."
How were BioLineRx's earnings last quarter?
BioLineRx (NASDAQ:BLRX) announced its earnings results on Tuesday, May, 22nd. The biotechnology company reported ($0.06) EPS for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.01. View BioLineRx's Earnings History.
When is BioLineRx's next earnings date?
What price target have analysts set for BLRX?
4 equities research analysts have issued 12-month price targets for BioLineRx's stock. Their forecasts range from $3.00 to $4.00. On average, they expect BioLineRx's stock price to reach $3.25 in the next year. View Analyst Ratings for BioLineRx.
What are Wall Street analysts saying about BioLineRx stock?
Here are some recent quotes from research analysts about BioLineRx stock:
- 1. According to Zacks Investment Research, "Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. " (5/25/2018)
- 2. Maxim Group analysts commented, "BiolineRx announced long-term follow-up data from the phase 2a study of BL-8040 (CXCR4 antagonist) in relapsed/refractory acute myeloid leukemia (r/ r AML) demonstrating improved overall survival (OS)." (12/4/2017)
- 3. HC Wainwright analysts commented, "AML Needle Continues to Point in Right Direction; Reiterate Buy Responses appear to impact survival in relapsed or refractory setting. This morning, BioLineRx announced long-term follow-up data from the BL-8040 Phase 2a in relapsed or refractory AML. Recall that in March 2016, topline results (n=42) were presented showing an overall response rate (CR+CRi) of 38%, which compared favorably to a historical control of approximately 20% (HiDAC alone). With longer observation in hand, the company is highlighting data from 16 patients in the expansion phase of the study: 1) median follow-up time of 338 days (29-853 days); 2) median overall survival of 11.1 months; and 3) estimated one- and two-year survival rates of 37.5% and 28.5%, respectively. While these patient numbers continue to be small, they continue to compare favorably with the expected overall survival of 6.1 months for HiDAC." (12/4/2017)
Are investors shorting BioLineRx?
BioLineRx saw a decrease in short interest in April. As of April 13th, there was short interest totalling 402,992 shares, a decrease of 24.7% from the March 30th total of 535,186 shares. Based on an average daily volume of 171,670 shares, the days-to-cover ratio is presently 2.3 days.
Who are some of BioLineRx's key competitors?
Some companies that are related to BioLineRx include Tyme Technologies (TYME), Kala Pharmaceuticals (KALA), Dermira (DERM), Minerva Neurosciences (NERV), Innovate (INNT), Bellicum Pharmaceuticals (BLCM), Unum Therapeutics (UMRX), Athersys (ATHX), Corbus Pharmaceuticals (CRBP), Corvus Pharmaceuticals (CRVS), Catalyst Pharmaceuticals (CPRX), Strongbridge Biopharma (SBBP), Paratek Pharmaceuticals (PRTK), Verastem (VSTM) and Seres Therapeutics (MCRB).
Who are BioLineRx's key executives?
BioLineRx's management team includes the folowing people:
- Mr. Philip A. Serlin, Chief Exec. Officer (Age 58)
- Ms. Mali Zeevi, CFO & Principal Accounting Officer (Age 42)
- Dr. Ella Sorani Ph.D., VP of Devel. (Age 50)
- Dr. Abi Vainstein-Haras M.D., VP of Clinical and Medical Affairs (Age 43)
- Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 66)
Has BioLineRx been receiving favorable news coverage?
News coverage about BLRX stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioLineRx earned a news sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of BioLineRx?
Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioLineRx's stock price today?
One share of BLRX stock can currently be purchased for approximately $0.91.
How big of a company is BioLineRx?
BioLineRx has a market capitalization of $96.91 million. The biotechnology company earns $-24,350,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. BioLineRx employs 43 workers across the globe.
How can I contact BioLineRx?
BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-2548-9100 or via email at [email protected]
MarketBeat Community Rating for BioLineRx (BLRX)
MarketBeat's community ratings are surveys of what our community members think about BioLineRx and other stocks. Vote "Outperform" if you believe BLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
BioLineRx (NASDAQ:BLRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for BioLineRx in the last 12 months. Their average twelve-month price target is $3.25, suggesting that the stock has a possible upside of 257.14%. The high price target for BLRX is $4.00 and the low price target for BLRX is $3.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $3.25 | $3.25 | $3.25 | $3.20 |
| Price Target Upside: | 257.14% upside | 225.00% upside | 200.93% upside | 181.94% upside |
BioLineRx (NASDAQ:BLRX) Consensus Price Target History
BioLineRx (NASDAQ:BLRX) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
BioLineRx (NASDAQ:BLRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
BioLineRx (NASDAQ BLRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 35.72%
BioLineRx (NASDAQ BLRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
BioLineRx (NASDAQ BLRX) News Headlines
| Source: |
|
BioLineRx (NASDAQ:BLRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
BioLineRx (NASDAQ:BLRX) Income Statement, Balance Sheet and Cash Flow Statement
BioLineRx (NASDAQ BLRX) Stock Chart for Sunday, May, 27, 2018
Loading chart…
